Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

Abstract

Background: The exploration of tumor-infiltrating lymphocytes (TILs) has gained significant attention in breast cancer research, particularly regarding their incidence and prognostic implications across various breast cancer subtypes. Literature Review: Further contributions from ( et al., 2015) emphasize the importance of categorizing TILs into stromal and intratumoral types, with stromal TILs showing greater prognostic stability, particularly in triple-negative breast cancer (TNBC). This classification is crucial for standardizing TIL assessment, as indicated by the International TIL Working Group's recommendations. The quantitative analysis performed by (Hayashi et al., 2022) further supports the prognostic value of CD8+ T cells across various cancers, reinforcing the need for a deeper understanding of the TME. The relationship between TILs and peripheral blood immune markers, as explored by (Onagi et al., 2022), reveals that high TIL levels correlate with better patient outcomes in TNBC, although challenges remain in assessing TILs in recurrent cases. The independent prognostic value of TILs is reaffirmed by (Schüler et al., 2022), who demonstrate that TILs can predict recurrence risk, particularly in TNBC and HER2-positive subtypes. The heterogeneity of immune cell infiltration across molecular subtypes is further explored by (Thanh Duong et al., 2023), who advocate for improved methodologies in assessing TILs, particularly in lymphocyte-predominant breast cancer. Finally, (Ciarka et al., 2024) synthesize the existing literature, reinforcing that while TILs are particularly meaningful in TNBC and HER2+ subtypes, their prognostic impact is limited in luminal breast cancers. Conclusion: In conclusion, the literature collectively underscores the complexity of TIL dynamics in breast cancer, highlighting their significant implications for prognosis and treatment response across different molecular subtypes. The evolving understanding of TILs as biomarkers necessitates ongoing research to standardize assessment methods and elucidate their roles in the TME, ultimately aiming to enhance clinical applicability and patient outcomes.